annual_results_press_conference_2019

Financial year 2018:  Boehringer Ingelheim grows and invests Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseasesOperating growth outpaces the market in all businessesTechnical integration of the animal health business acquired in 2017 successfully completed
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news